Aurora Cannabis Inc (ACB)

$6.71

-0.49

(-6.81%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Aurora Cannabis Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 50.21M → 64.41M (in $), with an average increase of 11.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -2.12M → -24.49M (in $), with an average decrease of 1051.8% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 35.3% return, outperforming this stock by 9.0%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 40.7% return, outperforming this stock by 132.3%

Performance

  • $6.71
    $7.07
    $6.71
    downward going graph

    0.0%

    Downside

    Day's Volatility :5.09%

    Upside

    5.09%

    downward going graph
  • $2.84
    $11.50
    $6.71
    downward going graph

    57.68%

    Downside

    52 Weeks Volatility :75.3%

    Upside

    41.65%

    downward going graph

Returns

PeriodAurora Cannabis IncSector (Health Care)Index (Russel 2000)
3 Months
80.41%
1.1%
0.0%
6 Months
68.97%
12.5%
0.0%
1 Year
26.29%
6.9%
2.2%
3 Years
-91.58%
14.3%
-23.0%

Highlights

Market Capitalization
342.5M
Book Value
$10.85
Earnings Per Share (EPS)
-57.38
Wall Street Target Price
31.92
Profit Margin
151.71%
Operating Margin TTM
-24.07%
Return On Assets TTM
-8.26%
Return On Equity TTM
-137.28%
Revenue TTM
275.9M
Revenue Per Share TTM
6.78
Quarterly Revenue Growth YOY
5.5%
Gross Profit TTM
21.2M
EBITDA
-33.3M
Diluted Eps TTM
-57.38
Quarterly Earnings Growth YOY
-0.92
EPS Estimate Current Year
-0.91
EPS Estimate Next Year
-0.31
EPS Estimate Current Quarter
-0.01
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Hold
    0
    0%Buy
    71%Hold
    28%Sell
Based on 14 Wall street analysts offering stock ratings for Aurora Cannabis Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
10
10
10
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 375.71%

Current $6.71
Target $31.92

Company Financials

FY18Y/Y Change
Revenue
55.2M
↑ 205.51%
Net Income
71.9M
↓ 654.72%
Net Profit Margin
130.33%
↑ 202.11%
FY19Y/Y Change
Revenue
189.4M
↑ 349.2%
Net Income
-222.2M
↓ 504.3%
Net Profit Margin
-117.3%
↓ 247.63%
FY20Y/Y Change
Revenue
205.5M
↑ 12.49%
Net Income
-2.4B
↑ 1038.21%
Net Profit Margin
-1.2K%
↓ 1069.6%
FY21Y/Y Change
Revenue
197.9M
↓ 12.07%
Net Income
-559.7M
↓ 79.05%
Net Profit Margin
-282.82%
↑ 904.08%
FY22Y/Y Change
Revenue
171.8M
↓ 9.75%
Net Income
-1.3B
↑ 147.63%
Net Profit Margin
-776.02%
↓ 493.2%
FY23Y/Y Change
Revenue
176.2M
↑ 5.4%
Net Income
-200.4M
↓ 84.55%
Net Profit Margin
-113.73%
↑ 662.29%
Q3 FY22Q/Q Change
Revenue
36.0M
↓ 1.9%
Net Income
-37.7M
↓ 91.66%
Net Profit Margin
-104.75%
↑ 1126.8%
Q4 FY22Q/Q Change
Revenue
45.6M
↑ 25.2%
Net Income
-48.3M
↑ 26.72%
Net Profit Margin
-106.02%
↓ 1.27%
Q1 FY23Q/Q Change
Revenue
53.3M
↑ 16.95%
Net Income
347.9M
↓ 819.44%
Net Profit Margin
652.2%
↑ 758.22%
Q2 FY23Q/Q Change
Revenue
37.9M
↓ 30.39%
Net Income
-467.4M
↓ 231.53%
Net Profit Margin
-1.2K%
↓ 1884.46%
Q3 FY23Q/Q Change
Revenue
63.4M
↑ 26.29%
Net Income
-2.1M
↓ 99.66%
Net Profit Margin
-3.35%
↑ 1228.91%
Q4 FY23Q/Q Change
Revenue
64.4M
↑ 1.58%
Net Income
-24.5M
↑ 1051.81%
Net Profit Margin
-38.03%
↓ 34.68%
FY18Y/Y Change
Total Assets
1.9B
↑ 492.14%
Total Liabilities
347.6M
↑ 235.03%
FY19Y/Y Change
Total Assets
4.2B
↑ 188.0%
Total Liabilities
850.1M
↑ 220.15%
FY20Y/Y Change
Total Assets
2.1B
↓ 49.41%
Total Liabilities
484.2M
↓ 40.94%
FY21Y/Y Change
Total Assets
2.1B
↓ 6.43%
Total Liabilities
457.5M
↓ 13.73%
FY22Y/Y Change
Total Assets
841.7M
↓ 58.37%
Total Liabilities
327.6M
↓ 25.58%
FY23Y/Y Change
Total Assets
699.7M
↓ 14.57%
Total Liabilities
309.1M
↓ 3.04%
Q3 FY22Q/Q Change
Total Assets
855.6M
↑ 7.89%
Total Liabilities
420.8M
↑ 36.36%
Q4 FY22Q/Q Change
Total Assets
756.3M
↓ 12.49%
Total Liabilities
316.8M
↓ 25.47%
Q1 FY23Q/Q Change
Total Assets
685.0M
↓ 9.52%
Total Liabilities
302.6M
↓ 4.59%
Q2 FY23Q/Q Change
Total Assets
819.1M
↑ 17.06%
Total Liabilities
318.8M
↑ 3.13%
Q3 FY23Q/Q Change
Total Assets
818.4M
↓ 24.53%
Total Liabilities
269.3M
↓ 36.18%
Q4 FY23Q/Q Change
Total Assets
817.2M
↓ 0.15%
Total Liabilities
259.0M
↓ 3.84%
FY18Y/Y Change
Operating Cash Flow
-81.7M
↑ 677.34%
Investing Cash Flow
-536.9M
↑ 988.04%
Financing Cash Flow
548.5M
↑ 148.97%
FY19Y/Y Change
Operating Cash Flow
-146.9M
↑ 135.4%
Investing Cash Flow
-238.6M
↓ 41.83%
Financing Cash Flow
456.5M
↑ 8.93%
FY20Y/Y Change
Operating Cash Flow
-249.0M
↑ 75.79%
Investing Cash Flow
-183.8M
↓ 20.11%
Financing Cash Flow
429.2M
↓ 2.51%
FY21Y/Y Change
Operating Cash Flow
-169.9M
↓ 37.69%
Investing Cash Flow
-21.7M
↓ 89.22%
Financing Cash Flow
421.2M
↓ 10.4%
FY22Y/Y Change
Operating Cash Flow
-85.3M
↓ 47.84%
Investing Cash Flow
-28.4M
↑ 36.03%
Financing Cash Flow
114.7M
↓ 71.69%
Q3 FY22Q/Q Change
Operating Cash Flow
-22.8M
↑ 16.88%
Investing Cash Flow
-30.7M
↑ 5.52%
Financing Cash Flow
-7.0M
↓ 115.53%
Q4 FY22Q/Q Change
Operating Cash Flow
-44.8M
↑ 94.77%
Investing Cash Flow
10.7M
↓ 134.59%
Financing Cash Flow
-46.1M
↑ 547.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.8M
↓ 60.37%
Investing Cash Flow
101.3K
↓ 99.06%
Financing Cash Flow
450.4K
↓ 100.98%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.1M
↑ 10.85%
Investing Cash Flow
-1.6M
↓ 1675.18%
Financing Cash Flow
46.9M
↑ 10087.03%

Technicals Summary

Sell

Neutral

Buy

Aurora Cannabis Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aurora Cannabis Inc
Aurora Cannabis Inc
71.02%
68.97%
26.29%
-91.58%
-99.34%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-1.55%
28.4%
35.29%
40.71%
79.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.71%
1.58%
-6.07%
12.69%
12.69%
Zoetis Inc.
Zoetis Inc.
-10.09%
-7.81%
-12.8%
-11.14%
48.17%
Viatris Inc.
Viatris Inc.
-2.37%
28.76%
25.82%
-14.76%
-29.31%
Catalent, Inc.
Catalent, Inc.
-0.8%
41.9%
32.08%
-51.64%
25.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aurora Cannabis Inc
Aurora Cannabis Inc
NA
NA
NA
-0.91
-1.37
-0.08
NA
10.85
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.72
56.72
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
30.04
30.04
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aurora Cannabis Inc
Aurora Cannabis Inc
Hold
$342.5M
-99.34%
NA
151.71%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
79.5%
56.72
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.4B
12.69%
30.04
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.17%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-29.31%
225.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
25.36%
211.02
-31.77%

Institutional Holdings

  • Renaissance Technologies Corp

    1.89%

  • Mirae Asset Global Investments (Korea) Co Ltd

    0.48%

  • Two Sigma Investments LLC

    0.31%

  • Susquehanna International Group, LLP

    0.28%

  • Yong Rong (HK) Asset Management Ltd

    0.28%

  • AXS Investments LLC

    0.21%

Corporate Announcements

  • Aurora Cannabis Inc Earnings

    Aurora Cannabis Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

aurora is a canadian company and licensed producer of artisanal medical marijuana pursuant to the marihuana for medical purposes regulations. we ensure the highest quality, reliability, and safety of our products through advanced cultivation techniques carried out in our 55,200 square foot expandable state-of-the-art production facility in alberta, canada. aurora’s wholly-owned subsidiary, australis capital inc., seeks to be an active participant in the u.s. cannabis market.

Organization
Aurora Cannabis Inc
Employees
1130
CEO
Mr. Miguel Martin
Industry
Health Technology

Discover More

FAQs